ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
11/06/2024
Back to search
Official data from USPTO
ERVIMMUNE
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
ERVIMMUNE
ST13
US500000097910441Class
5, 42, 44
Filing
97910441
Registration
7444894
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
21
Latest update
11/06/2024
Classification
Registered
Trademark type
Word
Nice classes
5, 42, 44
Filing date
04/27/2023
Registration date
07/09/2024
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/09/2024
Last transaction
07/09/2024
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Supplemental Register
Filing basis
Foreign priority
Drawing code
4
Owner type
99
Owner location
LYON CEDEX 08, FR
Examiner
THOMAS,AMY E
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
ERVIMMUNE
E. T. (pessoa física)
Representatives
Pina Campagna CARTER, DELUCA AND FARRELL LLP
Technical classification
Nice Classes
Class 5Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the treatment of cancer; therapeutic vaccines; Medical preparationsT-cell therapy preparations for the treatment of cancer; stem cells for medical use; biological preparations for the prevention and treatment of cancer; chemical preparations for pharmaceutical purposesfor the prevention and treatment of cancer; chemical preparations for medical purposesfor the prevention or treatment of cancer; medicinal preparations for the treatment of infectious diseases and for use in immunotherapy and oncology; all aforementioned goods not for use in the field of medical diagnostics
Class 42
Medical research laboratory services; biotechnological and pharmaceutical drug research and development services; pharmaceutical and biotechnological research and development; provision of medical and scientific research information in the field of pharmaceuticals; provision of medical and scientific research information in the field of therapeutic vaccines; provision of medical and scientific research information in the field of oncologyimmunotherapystem cell therapyT-cell therapy; Providing medical and scientific research information in the field of clinical trials; screening and selection of molecules for scientific and pharmacological research purposesnot for medical purposes; research and development in the field of immunotherapy; all aforementioned services not for use in the field of medical diagnostics
Class 44
Medical and surgical services in the field of immunotherapy and oncology; medical testing for treatment purposes; provision of medical information in the field of immunotherapy and oncology; medical analysis for the treatment of persons; genetic testing services for medical purposes; all aforementioned services not for use in the field of medical diagnostics
Publications
History of USPTO decisions and trademark events.
21 publications found
NRCS
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/09/2024
R.SR
REGISTERED-SUPPLEMENTAL REGISTER
07/09/2024
CNTA
APPROVED FOR REGISTRATION SUPPLEMENTAL REGISTER
05/31/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
05/29/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
05/28/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
05/28/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/04/2024
GNRT
NON-FINAL ACTION E-MAILED
04/04/2024
CNRT
NON-FINAL ACTION WRITTEN
04/04/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/23/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/22/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/25/2024
GNRT
NON-FINAL ACTION E-MAILED
01/25/2024
CNRT
NON-FINAL ACTION WRITTEN
01/25/2024
DOCK
ASSIGNED TO EXAMINER
01/24/2024
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
11/13/2023
ALIE
ASSIGNED TO LIE
11/13/2023
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
06/08/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/25/2023
NWAP
NEW APPLICATION ENTERED
05/01/2023
Continuous trademark protection
Get notified about every new filing that threatens ERVIMMUNE or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.